Sujit Sheth

Newborn Screening for Sickle Cell Disease and Thalassemia

First results of exagamglogene autotemcel in pediatric patients aged 5-11 years with transfusion-dependent β-thalassemia or sickle cell disease with recurrent severe vaso-occlusive crises

Durable Clinical Benefits in Transfusion-Dependent Β-Thalassemia with Exagamglogene Autotemcel

Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Αlpha-thalassemia: A practical overview

Diagnosis and management of pyruvate kinase deficiency: international expert guidelines

ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Transfusion Independence after Exagamglogene Autotemcel in Patients with Transfusion-Dependent β-Thalassemia

Thalassaemia—A global view

Luspatercept for transfusion-dependent β-thalassemia: time to get real

Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

S270: TRANSFUSION INDEPENDENCE AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA

Untreated Anemia in Nontransfusion-dependent β-thalassemia: Time to Sound the Alarm

Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers

Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells

Comorbidities and complications in adults with pyruvate kinase deficiency

Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency

Systematic Literature Review of the Burden of Disease and Treatment for Transfusion-dependent β-Thalassemia

Clinical and economic burden of regularly transfused adult patients with β‐thalassemia in the United States: A retrospective cohort study using payer claims

Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency

Long-Term Safety and Efficacy of Mitapivat (AG-348), a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency: The DRIVE PK Study

Association of Perioperative Red Blood Cell Transfusions With Venous Thromboembolism in a North American Registry

Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study

Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study

Results Update from the DRIVE PK Study: Effects of AG-348, a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency

Red blood cell transfusion is associated with increased hemolysis and an acute phase response in a subset of critically ill children